Specialty medications, which can cost between $10,000 and upward of $5 million, now account for 52% of U.S. pharmaceutical sales, according to a Dec. 30 report from the Healthcare Distribution ...

Q4 2025 Management View CEO Stephan Tanda emphasized "very strong top line performance" for Q4, with reported sales growing 14% to $963 million and core sales up 5%. Tanda noted, "Adjusted EBITDA ...

With sluggish pharmaceutical sales in the third quarter coming in below analysts’ expectations, Bayer is acutely aware of the challenges facing its key unit. Nevertheless, at least as far as ...

Total GAAP revenue reached $15.7 million in Q2 2025, outpacing the $13.8 million GAAP analyst estimate. Selling, general and administrative expenses (GAAP) rose to $54.3 million, driving a net loss ...

LONDON--(BUSINESS WIRE)--As coronavirus continues to wreak havoc across industries, Quantzig’s sales analytics experts analyze the recent challenges in the pharmaceutical industry and explain why a ...

Nearly 96 percent of U.S. pharmaceutical sales were brought to the market through pharmaceutical distributors in 2016, according to a new report published by the HDA Research Foundation, a healthcare ...

CEO David Zaccardelli highlighted the continued success of the Ohtuvayre launch for COPD maintenance treatment, with net product sales of $71.3 million in Q1 2025, nearly doubling from the previous ...

CEO Eric Green highlighted that the company achieved 3.3% organic revenue growth in Q4 2024, marking a return to quarterly growth. Notable drivers included strong performance in Biologics and the ...

ARS Pharmaceuticals specializes in developing and commercializing treatments for severe allergic reactions. Its flagship product, neffy, is a needle-free epinephrine nasal spray approved for emergency ...